Home›Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide

Also known as: Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide

Thiazide Diuretic

Route: Oral

Check Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide Interactions →

14 interactions on record⛔ Black Box Warning

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide has 14 known drug interactions based on U.S. FDA drug labeling data. Of these, 1 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aliskiren, Lithium, Mao Inhibitors. Patients taking Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 14
Contraindicated: 1
Major: 3
Moderate: 9

Contraindicated (1)

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Aliskiren— Do not co-administer with this combination in patients with diabetes. Avoid use in patients with renal impairment (GFR <…

Major (3)

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Lithium— Increases serum lithium concentrations and risk of lithium toxicity.
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Mao Inhibitors— May result in deterioration of renal function including possible acute renal failure and attenuate antihypertensive effe…
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Nsaids— May lead to increased risk of renal impairment, loss of antihypertensive effect, and deterioration of renal function inc…

Moderate (9)

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Amlodipine— Amlodipine ( 7.2 ): • Limit simvastatin to 20 mg daily when coadministered. • Increased exposure to cyclosporin and tacr…
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Cholestyramine Light— Reduces absorption of hydrochlorothiazide.
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Colesevelam Hydrochloride— Reduces systemic exposure and peak plasma concentration of olmesartan. Administer olmesartan at least 4 hours before col…
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Colestipol— Reduces absorption of hydrochlorothiazide.
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Cyclosporine— Amlodipine increases exposure to cyclosporin.
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Hydrochlorothiazide— • Increased exposure to cyclosporin and tacrolimus • Increased amlodipine exposure when coadministered with CYP3A inhibi…
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Olmesartan— 7 DRUG INTERACTIONS Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased…
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Simvastatin— Limit simvastatin to 20 mg daily when coadministered with amlodipine.
Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Tacrolimus— Amlodipine increases exposure to tacrolimus.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Aliskiren⛔Contraindicated

Do not co-administer with this combination in patients with diabetes. Avoid use in patients with renal impairment (GFR <60 ml/min) due to increased risks of hypotension, hyperkalemia, and acute renal failure.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Lithium⚠️Major

Increases serum lithium concentrations and risk of lithium toxicity.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Mao Inhibitors⚠️Major

May result in deterioration of renal function including possible acute renal failure and attenuate antihypertensive effect in elderly or volume-depleted patients.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Nsaids⚠️Major

May lead to increased risk of renal impairment, loss of antihypertensive effect, and deterioration of renal function including possible acute renal failure in elderly or volume-depleted patients.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Amlodipine🟡Moderate

Amlodipine ( 7.2 ): • Limit simvastatin to 20 mg daily when coadministered. • Increased exposure to cyclosporin and tacrolimus • Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. Closely monitor blood pressure, renal function and electrolytes in patients on olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets and other agents that affect the RAS.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Cholestyramine Light🟡Moderate

Reduces absorption of hydrochlorothiazide.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Colesevelam Hydrochloride🟡Moderate

Reduces systemic exposure and peak plasma concentration of olmesartan. Administer olmesartan at least 4 hours before colesevelam hydrochloride.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Colestipol🟡Moderate

Reduces absorption of hydrochlorothiazide.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Cyclosporine🟡Moderate

Amlodipine increases exposure to cyclosporin.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Hydrochlorothiazide🟡Moderate

• Increased exposure to cyclosporin and tacrolimus • Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. Closely monitor blood pressure, renal function and electrolytes in patients on olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets and other agents that affect the RAS. Do not co-administer aliskiren with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets in patients with diabetes [See Contraindications ( 4 )] .

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Olmesartan🟡Moderate

7 DRUG INTERACTIONS Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. • Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. 7.1 Drug Interactions with Olmesartan Medoxomil Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including olmesartan medoxomil, may result in deterioration of renal function, including possible acute renal failure.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Simvastatin🟡Moderate

Limit simvastatin to 20 mg daily when coadministered with amlodipine.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Tacrolimus🟡Moderate

Amlodipine increases exposure to tacrolimus.

Olmesartan Medoxomil And Amlodipine Besylate And Hydrochlorothiazide + Colesevelamℹ️Unknown

• Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. Use with Colesevelam Hydrochloride Concurrent administration of bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan. Administration of olmesartan at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.